India proposes immediate license suspension for drugs failing quality tests

India's new draft rules would force regulators to immediately suspend manufacturing licenses for drugs that fail government quality testing, a significant tightening of enforcement. The proposal targets persistent quality-control failures in the domestic pharma sector, which supplies a large share of global generic drugs. Impact on global supply chains and drug prices is uncertain pending final adoption.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works